

Construyendo Esperanza

INSTITUTIONAL REVIEW BOARD

Unanticipated Problem (UP)/ Serious Adverse Event (SAE) Report Form

For this form, a serious adverse event is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, results in congenital anomalies/birth defects, or by the opinion of the investigators represents other significant hazards or potentially serious harm to research subjects or others. A serious adverse event is considered unexpected if it is not described in the Package Insert or the Investigator's Brochure (for FDA investigational agents), in the protocol, or the informed consent document.

INSTRUCTIONS:

Please complete the information requested below and forward one copy to the IRB as soon as possible, but not later than seven (7) days in the case of death or life-threatening serious adverse events or within fifteen (15) days after the occurrence of all other forms of serious adverse events. The IRB office will immediately forward a copy to the Clinical Director. Also, continue to follow the FDA and the NIH Office reporting requirements if your research involves an IND/IDE or gene transfer.

PROTOCOL #:	PROT	OCOL TI	TLE:			
PRINCIPAL INVESTIGATOR:	Depar	tment:			Office Phone:	
	Fax:				E-mail:	
DATE OF SERIOUS ADVERSE EVENT:	/					
LOCATION OF SAE (e.g., at CCC or elsewhere):						
WAS THIS AN UNEXPECTED ADVERSE EVENT?	Yes [] No	[]			
WAS THIS A SERIOUS ADVERSE EVENT?	Yes [] No []					
BRIEF DESCRIPTION OF SUBJECT(S) (Do NOT	SEX:	M/	F	AGE:		
include identifiers.)		Diagnosis:				
BRIEF DESCRIPTION OF THE NATURE OF THE SERIOUS ADVERSE EVENT:						
CATEGORY (outcome) OF THE SERIOUS ADVERSE		RELATI	ONSH	IIP OF SERIOUS	ADVERSE EVENT TO RESEARCH:	
EVENT:						
[] death		[] 1 =	unrela	nted (clearly no	t related to the research)	
[] disability/incapacity		[] 2 = unlikely (doubtfully related to the research)				
[] life-threatening		[] 3 = possible (may be related to the research)				
[] congenital anomaly/birth defect		[] 4 = probable (likely related to the research)				
[] hospitalization-initial or prolonged		[] 5 = definite (clearly related to the research)				
[] required intervention to prevent permanent impairment						
[] other						
HAVE SIMILAR ADVERSE EVENTS OCCURRED ON	THIS	Yes []	No	[]		
PROTOCOL?	-	If "Yes,				
		Please		•		
			_ 0001			

What steps do you plan to take as a result of adverse event reported above? Provide documentation to the IRB for review and appany of the steps checked below.		 No action required Revise protocol to eliminate apparent immediate hazards to subjects Modification of inclusion or exclusion criteria to mitigate newly identified risks Implementation of additional procedures for monitoring subjects Suspension of enrollment of new subjects Notify currently enrolled subjects Suspension of research procedures in currently enrolled subjects Modification of consent documents to include a description of newly recognized risks (site and study-wide) Provision of additional information about newly recognized risks to previously enrolled subjects Terminate or suspend protocol Other:
Staff member completed this form (print):	Signature	re DATE:
Principal Investigator's name (print)	PI Signatu	ture DATE: